Josephine E Aideloje, NP
Nurse Practitioner · Lancaster
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 9 years
- Graduated 2017
Offices
2 locations · Los Angeles County Department of Mental Health · Inland Psychiatric Medical Group Inc
Looking this up.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Josephine E Aideloje’s office to ask if they take your plan before you enroll.
Original Medicare doctor bills
$12,917
Medicare paid this office $12,917 for 53 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 42 | $10,324 | $57 |
Who their Medicare patients are
53 Original Medicare patients in 2024. Average age 57 · Under 65 59% · Women 64% · Also on Medicaid 79% · Health risk score 1.35. At or below the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 57% · Depression 57% · Diabetes 21%.
The office billed $54,953, Medicare allowed $18,761 and paid $12,917; for 208 services of 9 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 53 | 208 | 57 | 1.35 | $54,953 | $12,917 |
| 2023 | 44 | 180 | 57 | 1.30 | $49,716 | $11,782 |
| 2022 | 30 | 137 | 54 | 1.48 | $31,568 | $8,881 |
| 2021 | 25 | 98 | 55 | 1.71 | $20,490 | $5,751 |
| 2020 | 19 | 56 | 58 | 1.05 | $13,150 | $3,147 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Short return visit (20+ min) | 37 | $8,305 | $58 |
| Return visit (30+ min) | 14 | $1,841 | $92 |
2022: 2 services
| Short return visit (20+ min) | 21 | $6,404 | $58 |
| Return visit (30+ min) | 11 | $1,303 | $81 |
2021: 2 services
| Short return visit (20+ min) | 22 | $3,553 | $47 |
| Psychiatric diagnostic evaluation with medical services | 12 | $1,413 | $118 |
2020: 2 services
| Psychiatric diagnostic evaluation with medical services | 11 | $1,109 | $101 |
| Short return visit (20+ min) | 11 | $779 | $37 |
Medicaid work
$62,792 in 2024
Medicaid paid $62,792 for 779 billed services this clinician did in 2024, up to 87 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 749 | $57,298 |
| Psychiatric diagnostic evaluation with medical services | 30 | $5,494 |
| 2024 | 779 | 2 | 87 | $62,792 |
| 2023 | 948 | 2 | 92 | $76,137 |
| 2022 | 1,164 | 3 | 100 | $100,344 |
| 2021 | 791 | 4 | 50 | $76,539 |
| 2020 | 475 | 3 | 46 | $36,539 |
| 2019 | 166 | 3 | 27 | $17,933 |
See the largest Medicaid services in earlier years
2023
| Short return visit (20+ min) | 931 | $73,491 |
| Psychiatric diagnostic evaluation with medical services | 17 | $2,646 |
2022
| Short return visit (20+ min) | 959 | $77,027 |
| Return visit (30+ min) | 152 | $15,072 |
| Psychiatric diagnostic evaluation with medical services | 53 | $8,246 |
2021
| Short return visit (20+ min) | 537 | $45,137 |
| Psychiatric diagnostic evaluation with medical services | 112 | $16,972 |
| Return visit (30+ min) | 125 | $13,597 |
| Short return visit | 17 | $833 |
2020
| Short return visit (20+ min) | 420 | $31,627 |
| Psychiatric diagnostic evaluation with medical services | 41 | $3,685 |
| Return visit (30+ min) | 14 | $1,227 |
2019
| Clinic visit/encounter, all-inclusive | 81 | $11,744 |
| Short return visit (20+ min) | 70 | $4,599 |
| Psychiatric diagnostic evaluation with medical services | 15 | $1,590 |
Drugs they prescribed that Part D paid
$162,954
Pharmacies billed $162,954 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 2,009) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
1,948 generic and 61 brand-name prescriptions · $162,954 in drug cost · 192 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Invega Sustenna | 27 | $66,099 | $2,448 |
| Caplyta | 11 | $20,843 | $1,895 |
| Rexulti | 12 | $16,240 | $1,353 |
| Aripiprazole | 115 | $4,774 | $42 |
| Quetiapine | 147 | $4,772 | $32 |
See all 38 drugs
| Invega Sustenna | 27 | $66,099 | $2,448 |
| Caplyta | 11 | $20,843 | $1,895 |
| Rexulti | 12 | $16,240 | $1,353 |
| Aripiprazole | 115 | $4,774 | $42 |
| Quetiapine | 147 | $4,772 | $32 |
| Olanzapine | 112 | $3,108 | $28 |
| Bupropion Xl | 115 | $2,163 | $19 |
| Doxepin | 26 | $2,053 | $79 |
| Trazodone | 211 | $2,001 | $9 |
| Ziprasidone | 23 | $1,533 | $67 |
| Risperidone | 68 | $1,202 | $18 |
| Hydroxyzine | 71 | $1,061 | $15 |
| Oxcarbazepine | 25 | $1,031 | $41 |
| Divalproex Sodium Er | 31 | $1,005 | $32 |
| Divalproex | 44 | $982 | $22 |
| Carbamazepine Er | 11 | $869 | $79 |
| Sertraline | 148 | $759 | $5 |
| Dextroamphetamine-Amphet Er | 18 | $706 | $39 |
| Lamotrigine | 92 | $694 | $8 |
| Gabapentin | 63 | $648 | $10 |
| Duloxetine | 32 | $590 | $18 |
| Mirtazapine | 41 | $498 | $12 |
| Venlafaxine Hcl Er | 40 | $496 | $12 |
| Lurasidone | 20 | $456 | $23 |
| Prazosin | 44 | $453 | $10 |
| Escitalopram | 67 | $451 | $7 |
| Haloperidol | 26 | $447 | $17 |
| Buspirone | 46 | $420 | $9 |
| Benztropine Mesylate | 45 | $412 | $9 |
| Fluoxetine | 50 | $397 | $8 |
| Bupropion | 27 | $354 | $13 |
| Atomoxetine | 15 | $347 | $23 |
| Lorazepam | 13 | $170 | $13 |
| Hydroxyzine Pamoate | 18 | $161 | $9 |
| Propranolol | 14 | $138 | $10 |
| Clonazepam | 32 | $112 | $4 |
| Lithium Carbonate | 18 | $77 | $4 |
| Citalopram Hbr | 36 | $55 | $2 |
Year by year
| 2024 | 2,009 | 138 | 0% (0) | 3% | $162,954 |
| 2023 | 1,593 | 107 | 0% (0) | 3% | $111,784 |
| 2022 | 1,039 | 86 | 0% (0) | 2% | $63,523 |
| 2021 | 927 | 82 | 0% (0) | 2% | $40,995 |
| 2020 | 527 | 82 | 0% (0) | 3% | $33,847 |
| 2019 | 44 | None | 0% (0) | 0% | $3,894 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 31 drugs
| Invega Sustenna | 11 | $25,367 | $2,306 |
| Rexulti | 15 | $23,380 | $1,559 |
| Aripiprazole | 106 | $8,823 | $83 |
| Quetiapine | 163 | $5,185 | $32 |
| Olanzapine | 85 | $4,923 | $58 |
| Trazodone | 166 | $4,084 | $25 |
| Bupropion Xl | 106 | $3,574 | $34 |
| Doxepin | 21 | $2,484 | $118 |
| Divalproex | 38 | $2,453 | $65 |
| Atomoxetine | 14 | $2,172 | $155 |
| Dextroamphetamine-Amphet Er | 22 | $1,868 | $85 |
| Venlafaxine Hcl Er | 35 | $1,742 | $50 |
| Hydroxyzine | 50 | $1,706 | $34 |
| Risperidone | 47 | $1,626 | $35 |
| Bupropion Hcl Sr | 23 | $1,443 | $63 |
| Fluoxetine | 37 | $1,219 | $33 |
| Sertraline | 117 | $1,039 | $9 |
| Lamotrigine | 58 | $1,003 | $17 |
| Escitalopram | 66 | $914 | $14 |
| Duloxetine | 30 | $895 | $30 |
| Buspirone | 35 | $763 | $22 |
| Mirtazapine | 33 | $762 | $23 |
| Gabapentin | 37 | $659 | $18 |
| Benztropine Mesylate | 37 | $537 | $15 |
| Hydroxyzine Pamoate | 28 | $526 | $19 |
| Ziprasidone | 17 | $383 | $23 |
| Oxcarbazepine | 12 | $351 | $29 |
| Prazosin | 17 | $281 | $17 |
| Bupropion | 26 | $257 | $10 |
| Citalopram Hbr | 30 | $74 | $2 |
| Lorazepam | 12 | $67 | $6 |
2022: 25 drugs
| Quetiapine | 99 | $8,591 | $87 |
| Aripiprazole | 53 | $6,460 | $122 |
| Duloxetine | 28 | $4,580 | $164 |
| Bupropion Xl | 51 | $4,498 | $88 |
| Olanzapine | 71 | $3,226 | $45 |
| Divalproex | 41 | $2,347 | $57 |
| Dextroamphetamine-Amphet Er | 12 | $1,876 | $156 |
| Trazodone | 103 | $1,314 | $13 |
| Sertraline | 73 | $1,098 | $15 |
| Risperidone | 42 | $1,072 | $26 |
| Hydroxyzine | 30 | $948 | $32 |
| Doxepin | 16 | $894 | $56 |
| Venlafaxine Hcl Er | 19 | $757 | $40 |
| Bupropion Hcl Sr | 20 | $680 | $34 |
| Oxcarbazepine | 12 | $659 | $55 |
| Fluoxetine | 68 | $536 | $8 |
| Benztropine Mesylate | 34 | $500 | $15 |
| Mirtazapine | 17 | $336 | $20 |
| Lamotrigine | 22 | $296 | $13 |
| Bupropion | 24 | $272 | $11 |
| Escitalopram | 47 | $264 | $6 |
| Hydroxyzine Pamoate | 20 | $216 | $11 |
| Buspirone | 25 | $156 | $6 |
| Levothyroxine | 11 | $56 | $5 |
| Lorazepam | 11 | $48 | $4 |
2021: 22 drugs
| Quetiapine | 103 | $3,377 | $33 |
| Aripiprazole | 49 | $2,764 | $56 |
| Bupropion Xl | 49 | $1,990 | $41 |
| Olanzapine | 73 | $1,523 | $21 |
| Duloxetine | 35 | $1,356 | $39 |
| Oxcarbazepine | 11 | $1,166 | $106 |
| Divalproex | 26 | $883 | $34 |
| Sertraline | 92 | $880 | $10 |
| Trazodone | 87 | $835 | $10 |
| Atomoxetine | 12 | $834 | $69 |
| Doxepin | 14 | $615 | $44 |
| Risperidone | 36 | $587 | $16 |
| Lamotrigine | 39 | $486 | $12 |
| Benztropine Mesylate | 30 | $454 | $15 |
| Hydroxyzine Pamoate | 22 | $376 | $17 |
| Hydroxyzine | 21 | $368 | $18 |
| Escitalopram | 18 | $330 | $18 |
| Venlafaxine Hcl Er | 12 | $300 | $25 |
| Bupropion Hcl Sr | 13 | $276 | $21 |
| Buspirone | 34 | $188 | $6 |
| Fluoxetine | 23 | $170 | $7 |
| Paroxetine | 14 | $69 | $5 |
2020: 18 drugs
| Quetiapine | 44 | $1,649 | $37 |
| Duloxetine | 16 | $1,208 | $76 |
| Ziprasidone | 11 | $897 | $82 |
| Olanzapine | 44 | $566 | $13 |
| Lamotrigine | 33 | $511 | $15 |
| Doxepin | 11 | $488 | $44 |
| Trazodone | 39 | $387 | $10 |
| Bupropion Xl | 20 | $381 | $19 |
| Divalproex | 14 | $263 | $19 |
| Benztropine Mesylate | 23 | $243 | $11 |
| Amitriptyline | 16 | $241 | $15 |
| Escitalopram | 16 | $240 | $15 |
| Hydroxyzine | 16 | $220 | $14 |
| Hydroxyzine Pamoate | 11 | $204 | $19 |
| Sertraline | 35 | $189 | $5 |
| Risperidone | 23 | $189 | $8 |
| Buspirone | 16 | $177 | $11 |
| Paroxetine | 11 | $125 | $11 |
Money from drug and device companies
$500 in 2025
| 2025 | 9 | 21 | None | $500 |
| 2024 | 5 | 10 | None | $219 |
| 2023 | 4 | 7 | None | $148 |
| 2022 | 1 | 3 | None | $157 |
| 2021 | 1 | 1 | None | $14 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Otsuka America Pharmaceutical | Rexulti | $185 | 7 payments
|
| Janssen Pharmaceuticals | Invega Sustenna | $101 | 4 payments
|
| Alkermes | Aristada | $62 | 2 payments
|
| Sage Therapeutics | Zurzuvae | $42 | 2 payments
|
| Lundbeck | Abilify Asimtufii | $37 | 2 payments
|
| Abbvie | Vraylar | $25 | 1 payment
|
See all 21 published payments
| Sage Therapeutics | Meals · 2025-12-19 | Zurzuvae | $24 |
| Otsuka America Pharmaceutical | Meals · 2025-12-12 | Rexulti | $32 |
| Otsuka America Pharmaceutical | Meals · 2025-11-21 | Rexulti | $30 |
| Corium | Meals · 2025-11-19 | Azstarys | $6 |
| Janssen Pharmaceuticals | Meals · 2025-11-07 | Invega Sustenna | $25 |
| Abbvie | Meals · 2025-10-24 | Vraylar | $25 |
| Otsuka America Pharmaceutical | Meals · 2025-10-17 | Rexulti | $31 |
| Janssen Pharmaceuticals | Meals · 2025-09-19 | Invega Sustenna | $25 |
| Alkermes | Meals · 2025-08-30 | Aristada | $29 |
| Lundbeck | Meals · 2025-08-22 | Abilify Asimtufii | $19 |
| Otsuka America Pharmaceutical | Meals · 2025-08-15 | Rexulti | $28 |
| Otsuka America Pharmaceutical | Meals · 2025-07-12 | Rexulti | $26 |
| Lundbeck | Meals · 2025-06-13 | Abilify Asimtufii | $18 |
| Otsuka America Pharmaceutical | Meals · 2025-05-26 | Abilify Asimtufii | $14 |
| Alkermes | Meals · 2025-05-09 | Aristada | $33 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-05-02 | Trintellix | $18 |
| Sage Therapeutics | Meals · 2025-04-25 | Zurzuvae | $18 |
| Janssen Pharmaceuticals | Meals · 2025-03-31 | Invega Sustenna | $18 |
| Neurocrine BioSciences | Meals · 2025-02-13 | Ingrezza | $24 |
| Otsuka America Pharmaceutical | Meals · 2025-02-07 | Rexulti | $24 |
| Janssen Pharmaceuticals | Meals · 2025-01-24 | Invega Sustenna | $32 |
See earlier years (2024, 2023, 2022, 2021)
2024: $219
| Janssen Pharmaceuticals | Invega Sustenna | $93 | 4 payments
|
| Neurocrine Biosciences | Ingrezza | $45 | 2 payments
|
| Lundbeck | Abilify Asimtufii | $41 | 2 payments
|
| Alkermes | Aristada | $27 | 1 payment
|
| Supernus Pharmaceuticals | Qelbree | $13 | 1 payment
|
2023: $148
| Axsome Therapeutics | Auvelity | $66 | 3 payments
|
| Lundbeck | Rexulti | $44 | 2 payments
|
| Otsuka America Pharmaceutical | Rexulti | $19 | 1 payment
|
| Janssen Pharmaceuticals | Invega Sustenna | $18 | 1 payment
|
2022: $157
| Teva Pharmaceuticals USA | Austedo | $157 | 3 payments
|
2021: $14
| AbbVie | Vraylar | $14 | 1 payment
|
Professional record
- NPI
- 1790272243
- Licence
- CA NP95007217
- Group
- Los Angeles County Department of Mental Health · Inland Psychiatric Medical Group Inc
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 363LP0808X (363LP0808X)
- Mailing address
- 6022 Starview Dr, Lancaster, CA, 93536
- NPI first listed
- 2018-04-20
- NPI last updated
- 2018-04-20
This is when the NPI record was last certified, not a medical board exam.